Implications on the Development of Animal Disease Models from FDA Modernization Act 2.0 / 实验动物与比较医学
Laboratory Animal and Comparative Medicine
; (6): 472-481, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1030701
Biblioteca responsable:
WPRO
ABSTRACT
Laboratory animals are the foundational conditions and indispensable technical support in life science research and biomedical industry development. The scientific development of animal models of diseases is of great significance to biomedical research and industrial development. In light of the booming development of multiple emerging in vitro modelling technologies over the past decade, in 2022, the U.S. Senate unanimously passed the bill FDA Modernization Act 2.0. This bill rescinded the requirement for animal testing in investigating the safety and effectiveness of a drug—a federal mandate since 1938, and highlighted the potential of various in vitro disease modeling approaches in future biomedical fields. This paper provides a comprehensive review of the latest advances and applications of in vitro disease modeling approaches in academia and industry followed by an interpretation of the FDA bill, namely cell culture, organoid, organ-on-a-chip, 3D bio-printing model and computer-based model. The paper next introduces the crossed applications of various disease models and discusses the advantages and disadvantages of each system, thereby providing insights into future trends in the use of animal disease models in China.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Laboratory Animal and Comparative Medicine
Año:
2023
Tipo del documento:
Article